Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Influenza A virus vaccine-H5N1; Influenza virus vaccine
- Indications Influenza A virus infections; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 24 Feb 2011 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Actual initiation date (1 May 2010) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.